Utang jangka cendhak perusahaan: biomerica.com (BMRA)

Biomerica, Inc. (BMRA) develops innovative food allergy detection panels, partnering with clinics and private individuals. The company is betting on affordable home diagnostics for intestinal pathologies and cancer via pharmacy retail. The price action for the separate_debt_short metric is currently at 0.00. The business is implementing AI systems and automation for autonomous screenings and the preparation of medical reports.

For Biomerica, Inc., which is developing the InFoods personalized diagnostics and testing ecosystem, this indicator reflects the volume of liabilities maturing within one year. By analyzing changes in short-term liabilities, an investor assesses pressure on working capital and the risk of cash flow gaps, which is critical for maintaining the company's operational activities during its active market scaling phase.